var data={"title":"Caffeine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Caffeine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5782?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=caffeine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Caffeine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=caffeine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Caffeine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144010\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Cafcit;</li>\n      <li>Keep Alert [OTC];</li>\n      <li>No Doz Maximum Strength [OTC];</li>\n      <li>Stay Awake Maximum Strength [OTC];</li>\n      <li>Stay Awake [OTC];</li>\n      <li>Vivarin [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144030\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Central Nervous System Stimulant;</li>\n      <li>\n        Phosphodiesterase Enzyme Inhibitor, Nonselective</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144013\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Caffeine citrate should not be interchanged with the caffeine sodium benzoate formulation. Dosing presented as the combination of caffeine and sodium benzoate unless otherwise noted (caffeine base amount is 50% of the caffeine and sodium benzoate combination).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Augmentation of seizure induction during electroconvulsive therapy (ECT) (off-label use): </b>IV: Initial: 500 to 1,000 mg caffeine and sodium benzoate (equivalent to 250 to 500 mg caffeine base); if necessary during subsequent ECT sessions, may titrate dose up or down in increments of 250 to 500 mg caffeine and sodium benzoate (equivalent to 125 to 250 mg caffeine base); a maximum dose of 2,000 mg caffeine and sodium benzoate (equivalent to 1,000 mg caffeine base) during an ECT session has been reported (Coffey 1987; Hinkle 1987; McCall 1993; Shapira 1987).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Postdural puncture headache (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 500 mg caffeine and sodium benzoate (equivalent to 250 mg caffeine base) in 1,000 mL NS infused over 1 hour, followed by 1,000 mL NS infused over 2 hours; after 4 hours, a second course of caffeine can be given for unrelieved headache pain (Choi 1996; Jarvis 1986; Yucel 1999).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 300 mg (caffeine base) as a single dose (Camann 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Stimulant:</b> OTC labeling: Oral: 100 to 200 mg (caffeine base) every 3 to 4 hours as needed</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144024\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=caffeine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Caffeine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Caffeine citrate should not be interchanged with the caffeine sodium benzoate formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Apnea of prematurity:</b> Neonates: Caffeine citrate: Oral, IV: <b>Note:</b> Dose expressed as caffeine citrate; caffeine base amount is 50% of caffeine citrate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Loading dose: Minimum dose: 20 mg/kg as caffeine citrate; loading doses as high as 80 mg/kg of caffeine citrate have been reported (Steer, 2004); some centers repeat a load of 20 mg/kg as caffeine citrate to a maximum cumulative dose load of 80 mg/kg as caffeine citrate in refractory patients (Schmidt, 2006; Schmidt, 2007; Steer, 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance dose: 5 to 10 mg/kg/day as caffeine citrate once daily starting 24 hours after the loading dose; some centers increase maintenance dose in 5 mg/kg/day increments of caffeine citrate to a maximum of 20 mg/kg/day in refractory patients based on clinical response &plusmn; serum caffeine concentrations (Schmidt, 2006; Schmidt, 2007; Steer, 2004).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144014\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144015\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling. Use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50087336\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling. Use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143990\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection, solution, as citrate [preservative free]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cafcit: 60 mg/3 mL (3 mL) [equivalent to 10 mg/mL caffeine base] </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 60 mg/3 mL (3 mL) [equivalent to 10 mg/mL caffeine base]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection, solution [with sodium benzoate]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: Caffeine 125 mg/mL and sodium benzoate 125 mg/mL (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, oral, as citrate [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cafcit: 60 mg/3 mL (3 mL) [equivalent to 10 mg/mL caffeine base] [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 60 mg/3 mL (3 mL) [equivalent to 10 mg/mL caffeine base]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Keep Alert: 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">NoDoz Maximum Strength: 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Stay Awake: 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Stay Awake Maximum Strength: 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vivarin: 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 200 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143978\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes: Tablet, caffeine and sodium benzoate injection, injection, oral solution</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143993\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: May be administered without regard to feedings or meals. May administer injectable formulation (caffeine citrate) orally.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Caffeine citrate:</b> Infuse loading dose over at least 30 minutes; maintenance dose may be infused over at least 10 minutes. May administer without dilution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Caffeine and sodium benzoate: Note:</b> Use a 0.22 micron in-line filter when administering (American Regent 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Direct IV injection, administer slowly.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Postdural puncture headaches (off-label use): Infuse diluted solution over 1 hour. Follow with 1,000 mL NS infused over 2 hours (Choi 1996; Jarvis 1986; Yucel 1999).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143992\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Caffeine citrate: Treatment of idiopathic apnea of prematurity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Caffeine and sodium benzoate: See Off-Label uses.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Caffeine [OTC labeling]: Restore mental alertness or wakefulness when experiencing fatigue</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25722060\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Augmentation of seizure induction during electroconvulsive therapy (caffeine and sodium benzoate); Postdural puncture headache (caffeine and sodium benzoate); CNS stimulant</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143983\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not specified; primarily serum-concentration related. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Cardiovascular: Angina pectoris, chest pain, flushing, palpitations, sinus tachycardia, supraventricular tachycardia, vasodilatation, ventricular arrhythmia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Agitation, delirium, dizziness, hallucination, headache, insomnia, irritability, psychosis, restlessness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Urticaria </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Esophageal motility disorder (sphincter tone decreased), gastritis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Diuresis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Fasciculations </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Increased intraocular pressure (&gt;180 mg caffeine), miosis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143996\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to caffeine or any component of the formulation; sodium benzoate is not for use in neonates</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143981\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anxiety: Avoid use in patients with anxiety, agitation, or tremor.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease; avoid use in patients with symptomatic cardiac arrhythmias.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal disease: Use with caution in patients with a history of peptic ulcer and/or gastroesophageal reflux.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorder: Use with caution in patients with a history of seizure disorder; may lower seizure threshold leading to new onset or breakthrough seizure activity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neonates: Caffeine citrate should be closely monitored for the development of necrotizing enterocolitis in the neonate; caffeine serum levels should be closely monitored to optimize therapy and prevent serious toxicity. Avoid use of products containing sodium benzoate in neonates; has been associated with a potentially fatal toxicity (&quot;gasping syndrome&quot;) in neonates, including metabolic acidosis, respiratory distress, gasping respirations, seizures, intracranial hemorrhage, hypotension, and cardiovascular collapse. <i>In vitro</i> and animal studies have shown that benzoate also displaces bilirubin from protein-binding sites.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; OTC products: OTC products contain 200 mg of caffeine per tablet approximately the amount of caffeine similar to one cup of coffee; limit the use of other caffeine-containing beverages or foods.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Product interchangeability: <b>Caffeine citrate should not be interchanged with caffeine and sodium benzoate.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings and precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Transcutaneous electrical nerve stimulation: Analgesia from transcutaneous electrical nerve stimulation may be lessened with concomitant caffeine use (Marchand 1995).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144025\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (major), CYP2C9 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP1A2 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143985\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9213&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acebrophylline: May enhance the stimulatory effect of CNS Stimulants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adenosine: Caffeine and Caffeine Containing Products may diminish the therapeutic effect of Adenosine.  Management: Monitor for decreased effect of adenosine if patient is receiving caffeine. Discontinue caffeine in advance of scheduled diagnostic use of adenosine whenever possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Caffeine and Caffeine Containing Products may decrease the absorption of Bromperidol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: May enhance the neuroexcitatory and/or seizure-potentiating effect of Agents With Seizure Threshold Lowering Potential.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<b> Exceptions: </b>Cannabidiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ciprofloxacin (Systemic): May increase the serum concentration of Caffeine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxofylline: Caffeine and Caffeine Containing Products may enhance the adverse/toxic effect of Doxofylline. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Formoterol: Caffeine and Caffeine Containing Products may enhance the adverse/toxic effect of Formoterol. Caffeine and Caffeine Containing Products may enhance the hypokalemic effect of Formoterol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indacaterol: Caffeine and Caffeine Containing Products may enhance the adverse/toxic effect of Indacaterol. Caffeine and Caffeine Containing Products may enhance the hypokalemic effect of Indacaterol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: Caffeine and Caffeine Containing Products may decrease the serum concentration of Lithium. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Norfloxacin: May increase the serum concentration of Caffeine and Caffeine Containing Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obeticholic Acid: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Olodaterol: Caffeine and Caffeine Containing Products may enhance the adverse/toxic effect of Olodaterol. Caffeine and Caffeine Containing Products may enhance the hypokalemic effect of Olodaterol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peginterferon Alfa-2b: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pipemidic Acid: May increase the serum concentration of Caffeine and Caffeine Containing Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Regadenoson: Caffeine and Caffeine Containing Products may diminish the vasodilatory effect of Regadenoson.  Management: Avoiding using caffeine or other methylxanthine containing products (e.g., theophylline) for at least 12 hours prior to the administration of regadenoson.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of Caffeine and Caffeine Containing Products.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teriflunomide: May decrease the serum concentration of Caffeine and Caffeine Containing Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TiZANidine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of TiZANidine.  Management: Avoid these combinations when possible.  If combined use is necessary, initiate tizanidine at an adult dose of 2 mg and increase in 2 to 4 mg increments based on patient response. Monitor for increased effects of tizanidine, including adverse reactions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vemurafenib: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors). Management: Consider alternatives to such combinations whenever possible, particularly if the CYP1A2 substrate has a relatively narrow therapeutic index.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143987\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143998\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. Caffeine crosses the placenta; serum concentrations in the fetus are similar to those in the mother (Grosso 2005). Based on current studies, usual dietary exposure to caffeine is unlikely to cause congenital malformations (Brent 2011). However, available data shows conflicting results related to maternal caffeine use and the risk of other adverse events, such as spontaneous abortion or growth retardation (Brent 2011; Jahanfar 2013). The half-life of caffeine is prolonged during the second and third trimesters of pregnancy and maternal and fetal exposure is also influenced by maternal smoking or drinking (Brent 2011; Koren 2000). Current guidelines recommend limiting caffeine intake from all sources to &le;200 mg/day (ACOG 2010).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143999\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Caffeine is detected in breast milk (Berlin 1981; Hildebrant 1983; Ryu 1985a); concentrations may be dependent upon maternal consumption and her ability to metabolize (eg, smoker versus nonsmoker) (Brent 2011). The ability of the breastfeeding child to metabolize caffeine is age-dependent (Hildebrant 1983). Irritability and jitteriness have been reported in the breastfeeding infant exposed to high concentrations of caffeine in breast milk (Mart&iacute;n 2007). Infant heart rates and sleep patterns were not found to be affected in normal, full-term infants exposed to lesser amounts of caffeine (Ryu 1985b).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143991\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Therapeutic: Apnea of prematurity: 8 to 20 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potentially toxic: &gt;20 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Toxic: &gt;50 mcg/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143980\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Increases levels of 3'5' cyclic AMP by inhibiting phosphodiesterase; CNS stimulant which increases medullary respiratory center sensitivity to carbon dioxide, stimulates central inspiratory drive, and improves skeletal muscle contraction (diaphragmatic contractility); prevention of apnea may occur by competitive inhibition of adenosine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143995\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates: 0.8 to 0.9 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &gt;9 months to Adults: 0.6 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 17% (children) to 36% (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic, via demethylation by CYP1A2. <b>Note:</b> In neonates, interconversion between caffeine and theophylline has been reported (caffeine levels are ~25% of measured theophylline after theophylline administration and ~3% to 8% of caffeine would be expected to be converted to theophylline)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates: 72 to 96 hours (range: 40 to 230 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &gt;9 months and Adults: 5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: Oral: Within 30 minutes to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates &le;1 month: 86% excreted unchanged in urine</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants &gt;1 month and Adults: In urine, as metabolites</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clearance:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates: 8.9 mL/hour/kg (range: 2.5 to 17)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 94 mL/hour/kg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323030\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Cafcit Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg/3 mL (3 mL): $42.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Caffeine Citrate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg/3 mL (3 mL): $34.12</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Caffeine Citrate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg/3 mL (3 mL): $28.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Caffeine-Sodium Benzoate Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125-125 mg/mL (2 mL): $21.88</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Caffeine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (16): $1.75</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (No Doz Maximum Strength Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (60): $6.90</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038545\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Cafcit (VN);</li>\n      <li>Cafnea (AU);</li>\n      <li>Coffeinum Natrium Benzoicum (PL);</li>\n      <li>Kofex (PL);</li>\n      <li>NeoCaf (KR);</li>\n      <li>Peyona (IE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists, &quot;ACOG Committee Opinion No. 462: Moderate Caffeine Consumption During Pregnancy,&quot; <i>Obstet Gynecol</i>, 2010, 116(2 Pt 1):467-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caffeine-drug-information/abstract-text/20664420/pubmed\" target=\"_blank\" id=\"20664420\">20664420</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berlin CM Jr, &quot;Excretion of Methylxanthines in Human Milk,&quot; <i>Semin Perinatol</i>, 1981, 5(4):389-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caffeine-drug-information/abstract-text/7302615/pubmed\" target=\"_blank\" id=\"7302615\">7302615</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brent RL, Christian MS, Diener RM. Evaluation of the reproductive and developmental risks of caffeine. <i>Birth Defects Res B Dev Reprod Toxicol</i>. 2011;92(2):152-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caffeine-drug-information/abstract-text/21370398 /pubmed\" target=\"_blank\" id=\"21370398 \">21370398 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Camann WR, Murray RS, Mushlin PS, Lambert DH. Effects of oral caffeine on postdural puncture headache. A double-blind, placebo-controlled trial. <i>Anesth Analg</i>. 1990;70(2):181-184.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caffeine-drug-information/abstract-text/2405733/pubmed\" target=\"_blank\" id=\"2405733\">2405733</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Choi A, Laurito CE, and Cunningham FE, &ldquo;Pharmacologic Management of Postdural Puncture Headache,&rdquo; <i>Ann Pharmacother</i>, 1996, 30(7-8):831-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caffeine-drug-information/abstract-text/8826568/pubmed\" target=\"_blank\" id=\"8826568\">8826568</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"3580438\"></a>Coffey CE, Weiner RD, Hinkle PE, Cress M, Daughtry G, Wilson WH. Augmentation of ECT seizures with caffeine. <i>Biol Psychiatry</i>. 1987;22(5):637-649.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caffeine-drug-information/abstract-text/3580438/pubmed\" target=\"_blank\" id=\"3580438\">3580438</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fratto G, Manzon L. Use of psychotropic drugs and associated dental diseases. <i>Int J Psychiatry Med.</i> 2014;48(3):185-197.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caffeine-drug-information/abstract-text/25492713/pubmed\" target=\"_blank\" id=\"25492713\">25492713</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grosso LM, Bracken MB. Caffeine metabolism, genetics, and perinatal outcomes: a review of exposure assessment considerations during pregnancy. <i>Ann Epidemiol</i>. 2005;15(6):460-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caffeine-drug-information/abstract-text/15967394 /pubmed\" target=\"_blank\" id=\"15967394 \">15967394 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hildebrandt R and Gundert-Remy U, &quot;Lack of Pharmacological Active Saliva Levels of Caffeine in Breast-Fed Infants,&quot; <i>Pediatr Pharmacol</i>, 1983, 3(3-4):237-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caffeine-drug-information/abstract-text/6677875/pubmed\" target=\"_blank\" id=\"6677875\">6677875</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"3631312\"></a>Hinkle PE, Coffey CE, Weiner RD, Cress M, Christison C. Use of caffeine to lengthen seizures in ECT. <i>Am J Psychiatry</i>. 1987;144(9):1143-1148.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caffeine-drug-information/abstract-text/3631312/pubmed\" target=\"_blank\" id=\"3631312\">3631312</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Important drug administration information: caffeine and sodium benzoate injection, USP, 250 mg/mL (125 mg/mL caffeine) 2 mL single dose vials. American Regent website. http://www.americanregent.com/pdf/DICSB_JUL_2016.pdf. Published July 18, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jahanfar S, Jaafar SH. Effects of restricted caffeine intake by mother on fetal, neonatal and pregnancy outcome. <i>Cochrane Database Syst Rev</i>. 2013;2:CD006965.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caffeine-drug-information/abstract-text/23450573 /pubmed\" target=\"_blank\" id=\"23450573 \">23450573 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jarvis AP, Greenawalt JW, Fagraeus L. Intravenous caffeine for postdural puncture headache. <i>Anesth Analg</i>. 1986;65(3):316-317.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caffeine-drug-information/abstract-text/3954102/pubmed\" target=\"_blank\" id=\"3954102\">3954102</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koren G, &ldquo;Caffeine During Pregnancy? In Moderation,&rdquo; <i>Can Fam Physician</i>, 2000, 46(4):801-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caffeine-drug-information/abstract-text/10790810/pubmed\" target=\"_blank\" id=\"10790810\">10790810</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marchand S, Li J, Charest J. Effects of caffeine on analgesia from transcutaneous electrical nerve stimulation. <i>N Engl J Med</i>. 1995;333(5):325-326.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caffeine-drug-information/abstract-text/7596392/pubmed\" target=\"_blank\" id=\"7596392\">7596392</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mart&iacute;n I, L&oacute;pez-V&iacute;lchez MA, Mur A, et al, &quot;Neonatal Withdrawal Syndrome After Chronic Maternal Drinking of Mate,&quot; <i>Ther Drug Monit</i>, 2007, 29(1):127-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caffeine-drug-information/abstract-text/17304161/pubmed\" target=\"_blank\" id=\"17304161\">17304161</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8379563\"></a>McCall WV, Reid S, Rosenquist P, Foreman A, Kiesow-Webb N. A reappraisal of the role of caffeine in ECT. <i>Am J Psychiatry</i>. 1993;150(10):1543-1545.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caffeine-drug-information/abstract-text/8379563/pubmed\" target=\"_blank\" id=\"8379563\">8379563</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ryu JE, &quot;Caffeine in Human Milk and in Serum of Breast-Fed Infants,&quot; <i>Dev Pharmacol Ther</i>, 1985a, 8(6):329-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caffeine-drug-information/abstract-text/4075932/pubmed\" target=\"_blank\" id=\"4075932\">4075932</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ryu JE, &quot;Effect of Maternal Caffeine Consumption on Heart Rate and Sleep Time of Breast-Fed Infants,&quot; <i>Dev Pharmacol Ther</i>, 1985b, 8(6):355-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caffeine-drug-information/abstract-text/4075934/pubmed\" target=\"_blank\" id=\"4075934\">4075934</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schmidt B, Roberts RS, Davis P, et al.; Caffeine for Apnea of Prematurity Trial Group. Caffeine therapy for apnea of prematurity. <i>N Engl J Med</i>. 2006;354(20):2112-2121.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caffeine-drug-information/abstract-text/16707748/pubmed\" target=\"_blank\" id=\"16707748\">16707748</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schmidt B, Roberts RS, Davis P, et al.; Caffeine for Apnea of Prematurity Trial Group. Long-term effects of caffeine therapy for apnea of prematurity. <i>N Engl J Med</i>. 2007;357(19):1893-1902.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caffeine-drug-information/abstract-text/17989382/pubmed\" target=\"_blank\" id=\"17989382\">17989382</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sechzer PH, Abel L. Post-spinal anesthesia headache treated with caffeine. Evaluation with demand method. Part I. <i>Current Therapeutic Research</i>. 1978;24(3):307-312.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"3631318\"></a>Shapira B, Lerer B, Gilboa D, Drexler H, Kugelmass S, Calev A. Facilitation of ECT by caffeine pretreatment. <i>Am J Psychiatry</i>. 1987;144(9):1199-1202.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caffeine-drug-information/abstract-text/3631318/pubmed\" target=\"_blank\" id=\"3631318\">3631318</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Steer P, Flenady V, Shearman A, et al.; Caffeine Collaborative Study Group Steering Group. High dose caffeine citrate for extubation of preterm infants: a randomised controlled trial. <i>Arch Dis Child Fetal Neonatal Ed</i>. 2004;89(6):F499-503.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caffeine-drug-information/abstract-text/15499141/pubmed\" target=\"_blank\" id=\"15499141\">15499141</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tyrala EE and Dodson WE, &quot;Caffeine Secretion Into Breast Milk,&quot; <i>Arch Dis Child</i>, 1979, 54(10):787-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caffeine-drug-information/abstract-text/507903/pubmed\" target=\"_blank\" id=\"507903\">507903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9952095\"></a>Y&uuml;cel A, Ozyal&ccedil;in S, Talu GK, Y&uuml;cel EC, Erdine S. Intravenous administration of caffeine sodium benzoate for postdural puncture headache. <i>Reg Anesth Pain Med</i>. 1999;24(1):51-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caffeine-drug-information/abstract-text/9952095/pubmed\" target=\"_blank\" id=\"9952095\">9952095</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9213 Version 142.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F144010\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F144030\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F144013\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F144024\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F144014\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F144015\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F50087336\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F143990\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F143978\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F143993\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F143992\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25722060\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F143983\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F143996\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F143981\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F144025\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F143985\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F143987\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F143998\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F143999\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F143991\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F143980\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F143995\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323030\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038545\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9213|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=caffeine-patient-drug-information\" class=\"drug drug_patient\">Caffeine: Patient drug information</a></li><li><a href=\"topic.htm?path=caffeine-pediatric-drug-information\" class=\"drug drug_pediatric\">Caffeine: Pediatric drug information</a></li></ul></div></div>","javascript":null}